GlassScriptPhysician profile
Naira Asatrian
NPI 1912153131
$9,709.80
in general payments reported to CMS, 2019-2025
35 companies · $2,807 in 2025
The $2,807 reported for 2025 was more than what 98% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,531 · 2022: $1,922 · 2023: $1,182 · 2024: $2,268 · 2025: $2,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,082 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,081.71 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,269.57 | 2021-2025 | Jardiance |
| Amgen INC. | $1,178.38 | 2021-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $1,024.35 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,011.05 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $806.25 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $613.55 | 2021-2025 | |
| Abbvie INC. | $453.07 | 2021-2025 | |
| Glaxosmithkline, LLC. | $391.69 | 2021-2023 | Arexvy |
| Phathom Pharmaceuticals, INC. | $374.99 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $161.99 | 2024-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $157.56 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $147.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $141.04 | 2022-2025 | Zoryve |
| Neurocrine Biosciences, INC. | $139.77 | 2024 | Ingrezza |
| Agios Pharmaceuticals, INC. | $137.39 | 2024 | Pyrukynd |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $135.19 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Aimmune Therapeutics, INC. | $123.63 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.77 | 2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $122.52 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $121.88 | 2024 | Bylvay |
| Madrigal Pharmaceuticals | $121.06 | 2025 | Rezdiffra |
| Vanda Pharmaceuticals INC. | $117.93 | 2021-2023 | Hetlioz |
| Pfizer INC. | $116.49 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $108.36 | 2021 | |
| Abiomed | $101.11 | 2025 | |
| Gilead Sciences, INC. | $100.00 | 2021 | |
| Neurelis, INC. | $94.93 | 2022 | |
| Esperion Therapeutics, INC. | $66.87 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $57.50 | 2022-2023 | Linzess |
| Daiichi Sankyo INC. | $57.49 | 2021 | |
| Shield Therapeutics INC | $40.52 | 2023-2024 | Accrufer |
| Nevro Corp. | $34.96 | 2023 | Senza |
| Exact Sciences Corporation | $25.59 | 2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $16.93 | 2021 | |
| Mylan Specialty L.P. | $16.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naira Asatrian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.